Clin Liver Dis. 2020 Nov;24(4):739-753
Authors: Armstrong SA, He AR
Abstract
Hepatocellular carcinoma is a highly prevalent and lethal cancer that many therapeutics are being tested for this disease. It has the potential to be a highly immune-responsive tumor given its inflammatory origins. The first immunotherapies were anti-programmed death-1 monotherapies, which improved response rates and survival. Novel immunotherapy combinations and immunotherapy show promise in frontline treatment. The novel antibody therapy combination of atezolizumab and bevacizumab may be practice changing. Although these landmark studies seem to offer new treatment options, the role of immunotherapy in the liver transplant setting is uncertain until the safety of this approach is defined.
PMID: 33012456 [PubMed - in process]
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου